Drug file · From the Watchtower
Welireg: the briefings and the record
Every Prognyx briefing on Welireg, newest first, and the dated events drawn from the sources those briefings cite. Rebuilt with each new briefing.
- Also known as
- Belzutifan, MK-6482
- Target, as briefed
- HIF-2α inhibitor + multi-targeted VEGFR tyrosine kinase inhibitor; HIF-2α inhibitor
- Companies named
- Merck & Co. (MSD), Merck, Eisai
- Prognyx coverage
- 2 briefings, 25 September 2026 to 13 November 2026
Prognyx briefings on Welireg
- advanced renal cell carcinoma with a clear cell component, post anti-PD-1/PD-L1 therapyBelzutifan plus lenvatinib wins positive EU CHMP opinion in kidney cancer
Merck's HIF-2alpha inhibitor combination clears Europe's scientific committee for ccRCC after PD-(L)1 therapy, on LITESPARK-011 progression-free survival data.
- advanced clear-cell renal cell carcinomaPer Endpoints, Merck's Welireg-Lenvima wins FDA approval in advanced ccRCC
The FDA approved belzutifan plus Eisai's lenvatinib on 24 September 2026 for adults with advanced renal cell carcinoma with a clear-cell component after a PD-1 or PD-L1 inhibitor, pushing the HIF-2α inhibitor past its VHL-disease niche.
Sourced timeline
Readouts, regulatory actions, filings, trial starts and deals that the Prognyx engine extracted from the documents cited in these briefings, newest first. Each links to its source and to the briefing that cited it. Press coverage is left out, and so is any event dated on its own briefing's day: the briefing above is the record for that day. A month without a day is a date the source gave only to the month.
- Regulatory actionFDA approves belzutifan + lenvatinib for advanced RCC with clear cell componentFDA · cited in Belzutifan plus lenvatinib wins positive EU CHMP opinion in kid…
- Trial startMerck initiates Phase 3 LITESPARK-034 (belzutifan + zanzalintinib)SEC 8-K (Exelixis) · cited in Per Endpoints, Merck's Welireg-Lenvima wins FDA approval in adv…
- Trial startMerck initiates Phase 3 LITESPARK-034 (belzutifan + zanzalintinib)SEC 8-K (Exelixis) · cited in Belzutifan plus lenvatinib wins positive EU CHMP opinion in kid…
- Regulatory actionEU approval for belzutifan in RCCUrology Times · cited in Per Endpoints, Merck's Welireg-Lenvima wins FDA approval in adv…
Registered trials on file
ClinicalTrials.gov records that the cited sources tie to Welireg, each opening on the registry.
- NCT07840001 Neoadjuvant belzutifan +/- pembrolizumab in high-risk ccRCC
- NCT07489495 LITESPARK-034
- NCT06428396 LITESPARK-029
- NCT05899049 MK-6482-012 China Extension
- NCT05468697 LITESPARK-024
- NCT04489771 MK-6482-013
- NCT02974738 MK-6482-001
The Watchtower, by email
The next move on Welireg, the day it happens.
The next readout, FDA/EMA action or deal on Welireg reaches you by email the day we publish it. One email per briefing, nothing else.
Double opt-in. Never sold, no open tracking. Privacy.
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.
Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use. Event titles are written by the Prognyx engine from the linked source; the source is the record.